Cancer Research Targets Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katayama, M.
Right arrow Articles by Sekiguchi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katayama, M.
Right arrow Articles by Sekiguchi, K.
[Cancer Research 63, 222-229, January 2003]
© 2003 American Association for Cancer Research

Tumor Biology

Laminin {gamma}2-Chain Fragment in the Circulation

A Prognostic Indicator of Epithelial Tumor Invasion

Masahiko Katayama1, Noriko Sanzen, Akihiro Funakoshi and Kiyotoshi Sekiguchi

Diagnostic Department, Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635 [M. K.]; Division of Gastroenterology, National Kyushu Cancer Center, Fukuoka 815-1347 [A. F.]; Institute for Protein Research, Osaka University, Suita, Osaka 565-0871 [N. S., K. S.]; and Sekiguchi Biomatrix Signaling Project, ERATO, Japan Science and Technology Corporation, Nagakute, Aichi 480-1195 [N. S., K. S.], Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Laminin (LN) 5, the major component of epithelial-derived extracellular matrix (ECM), plays a major role in cell adhesion and motility. Previous reports stated that proteolytic processing of the NH2-terminal region of the {gamma}2 chain enhances cell motility on LN5, indicating that the degraded {gamma}2 chain NH2-terminal region would be shed from the ECM. However, soluble LN {gamma}2 NH2-terminal fragment (G2F) have not been detected in biological fluids. Here, we developed a double-monoclonal electrochemiluminescence immunoassay for human G2F and detected its presence in the normal human circulation (mean ± SD: 39.2 ± 10.3 ng/ml; n = 10). We also measured serum levels of G2F in nude mice orthotopically transplanted with three different human pancreatic carcinoma cell lines: MIApaca-II (secreting no LN5), HPAC (secreting the {alpha}3ß3{gamma}2 heterotrimer of LN5), or KP-1 (secreting the monomeric {gamma}2 chain of LN5). Serum levels of G2F drastically increased in the nude mice transplanted with HPAC (mean ± SD: 351 ± 33 ng/ml, 5 weeks after transplantation), the most invasive tumor cells to generate extensive peritoneal dissemination in vivo. A moderate increase in serum levels of G2F was also observed in mice transplanted with KP-1 (87.9 ± 82 ng/ml, 5 weeks after transplantation), but no antigen was detected in the sera of MIApaca-II-transplanted mice. Therefore, circulating G2F was demonstrated to be a sensitive marker for LN5 production of primary pancreatic carcinomas, even if it was produced only as a monomeric {gamma}2 chain. In 11 established human pancreatic tumor cell lines (6 of LN5-producing cells and 5 of nonproducing cells), LN5-secreting cells have significantly higher levels of cell surface expression of ß4 integrin than nonsecreting cells. Thus, LN5 secretion is accompanied by cell surface expression of {alpha}6ß4 integrin, participating in hemidesmosome reorganization to form invading edges of malignant epithelial carcinomas. These data reveal that the level of circulating G2F is a new, prognostic, tumor-characterizing marker for estimating the invasiveness and malignancy of epithelial carcinomas in cancer patients.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Members of the LN2 family of glycoproteins are major constituents of basement membranes (basal lamina), ECM components found in intimate contact with individual cells and cell layers (1) . LNs have one heavy chain, {alpha}, and two light chains, designated ß and {gamma}, so 15 genetically distinct LN types are known at present (1 , 2) . LN5 is found in the basement membrane of epithelia, known as a major component of the anchoring filaments, and plays an important role in stabilizing the attachment of epithelial hemidesmosomes to the basement membrane via {alpha}6ß4 integrin (2, 3, 4) . Our present study is focused on the degradation and solubilization of the LN {gamma}2 NH2-terminal region. The 155 kDa mature form of the {gamma}2 chain is cleaved into a 105 kDa COOH-terminal fragment, and some proteases mediate this extracellular processing to shed the globular domain IV and the epidermal growth factor-like rich domain V of the {gamma}2 short arm from the 440 kDa high molecular weight form of LN5 (5) . MMP2 (6) , MT1-MMP (7) , and bone morphogenic protein-1/type-I procollagen COOH-terminal peptidase (8) are considered to be candidates for LN {gamma}2-processing proteases. The COOH-terminal fragments of LN {gamma}2, with a molecular weight of 105 kDa, were shown previously to be additionally processed into the 80 kDa forms by MT1-MMP (7) . The resultant degraded LN5 (400 kDa heterotrimer) is an active form that enhances epithelial cell motility and migration in vitro (6 , 7) . Therefore, the proteolytic release of the NH2-terminal region of the {gamma}2 chain can be an indicator for invasive LN5 deposition in the anchoring edges of epithelial cells. However, the contributions of the {gamma}2 NH2-terminal domain processing to hemidesmosome turnover or reorganization of LN5-rich anchoring contacts, probably acting in the epithelial cell invasion during tissue remodeling, are not well understood and require additional study (9) .

LN5 is known as one of the major scattering factors stimulating the invasive and metastatic ability of several types of tumor cells (10 , 11) . Some recent histochemical studies revealed that the {gamma}2 chain of LN5 is strongly expressed in disseminating and infiltrating tumor cells at the invasive front of epithelial carcinomas, and its increased expression in tumor tissues is associated with poor prognosis (12, 13, 14, 15) . Another study reported that the monomeric {gamma}2 chain (not associated with the {alpha}3 or ß3 chain) is expressed as a single subunit specifically in some invading tumor cells (16) . A recent interesting report demonstrated a correlated expression of the transcriptional regulator nuclear ß-catenin and the LN {gamma}2 chain in dedifferentiated tumor cells at the invasive site of carcinomas, suggesting that overexpression of LN {gamma}2 in tissues is a potential marker of invasion of malignant and metastatic cancers (17) .

Measurements of the concentration of soluble LN5 in cell culture supernatants were reported previously, but only in human keratinocytes (18) . However, LN5 or its degraded fragments have not been detected yet in the biological circulation. Here, we developed an immunoassay system to measure the levels of soluble G2F and found that they are present in the normal human circulation. Additionally, we found that the concentration of fragments increased gradually in the circulation of experimental animals bearing human carcinoma cell lines, correlatively with the growth of the orthotopically transplanted tumors. We also showed that high levels of expression of cell surface {alpha}6ß4 integrins can be observed with some of the human pancreatic carcinoma cell lines, synergistic with their ability to produce LN5 extracellularly. Here, we presumed that the cellular secretion of LN5 may be accompanied by the cell surface expression of its receptor, {alpha}6ß4 integrin. {alpha}6ß4 integrins on epithelial carcinoma cells are well known to be up-regulated correlatively with hemidesmosome reorganization in their invasive growth area, and localized in membrane protrusions associated with migration such as filopodia and lamellipodia (19) . Thus, it was clearly shown that protease-mediated LN5 remodeling and expression of the counter receptor integrins on epithelial tumor cells contribute simultaneously to their invasion into the surrounding stroma, as suggested by the other reports (6 , 7 , 20) . Therefore, the presence of G2F in the circulation is a new potential tumor marker for estimating invasiveness, by determining the accumulation of active LN5 and {alpha}6ß4 integrin expression in the invasive fronts.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines.
KP-1, KP-2, KP-3, KP-4, SUIT-2, and BxPC-3 human pancreatic tumor cell lines were established as reported previously (21) . Ten human tumor cell lines, including the breast carcinoma cell line T-47D, the lung carcinoma cell line A549, the gastric carcinoma cell line KATO-III, the gastric carcinoma cell line MKN45, the colorectal adenocarcinoma cell line COLO205, the osteosarcoma cell line MG-63, the fibrosarcoma cell line HT-1080, the cervical carcinoma cell line HeLa-S3, the glioblastoma cell line A-172, and the mouth epidermal carcinoma cell line KB were purchased from the Laboratory Products Department of Dainippon Pharmaceutical Co., Ltd (Osaka, Japan). Human glioblastoma cell lines SK-N-SH and U-251 MG were provided from RIKEN Cell Bank (Wako, Japan). All of the other human tumor cell lines including 5 human pancreatic carcinoma cell lines (AsPC-1, HPAC, PSN-1, MIApaca-II, and PANC-1) used in this study were obtained from the American Type Culture Collection (Rockville, MD). All of the cell lines were cultured in RPMI 1640 (Sigma Chemical Co., St. Louis, MO) supplemented with streptomycin, penicillin, and 10% FCS (5 x 106 cells/75 cm2 tissue culture flask in 25 ml culture medium) for 24 (KP-1, KP-2, KP-3, KP-4, AsPC-1, HPAC, SUIT-2, MIApaca-II, PSN-1, BxPC-3, PANC-1, MDA-MB435, T-47D, MDA-MB453, ZR-75-1, MCF-7, HT-29, SW620, NCI-H596, PC-14, A549, MKN45, DU145, PC-3, MG-63, U251, SK-N-SH, HeLa-S3, and KB) or 72 h (KATO-III, LX-1, WiDr, COLO205, LoVo, KP-1, and MIApaca-II) at 37°C in a humidified atmosphere containing 5% CO2.

Immunogens and MoAbs.
Human LN5 was immunoisolated from MKN45 cell culture supernatants (11) . The monomeric {gamma}2 chain and the heterodimeric ß3{gamma}2 chains of human LN5 were isolated from A-172 and HT-1080 cell culture supernatants, respectively, essentially according to the previous procedure (11) . BALB/c mice were immunized with LN5, and hybridomas secreting MoAbs reactive with LN5 were constructed according to the standard method (22) . In the first trial, we established 4 hybridoma cell lines producing anti-LN5 MoAbs (19, 57, 2B10, and 8C2). The monomeric {gamma}2 chain purified from A-172 cell culture supernatants, the LN5 heterodimer consisted with ß3{gamma}2 purified from HT-1080 cell culture supernatants, or the whole LN5 heterotrimers were absorbed onto microplates separately and used in an indirect ELISA for these MoAbs. Antihuman LN5 rabbit antiserum (11) was diluted appropriately and used as a positive control. Binding of antibodies to the various LN5 derivates immobilized on the plates was estimated by using peroxidase-labeled second antibodies and o-phenylenediamine substrates (Sigma Chemical Co.). In addition, 10 mg IgG of 8C2 MoAbs were immobilized onto cyanogen bromide-activated Sepharose 4B (Amersham Pharmacia Biotech AB, Uppsala, Sweden) according to the manufacturer’s instructions and used to immunoisolate the {gamma}2 fragments of LN from the culture supernatants of human pancreatic carcinoma cell lines, KP-2 or BxPC-3. LN5 or its degraded fragments, eluted by 8 M urea from 8C2 MoAbs coupled to cyanogen bromide-activated Sepharose, was dialyzed against PBS. In the trial to construct the next murine hybridomas, we used this KP-2-derived LN5 as an immunogens to generate 2 new hybridomas secreting anti-LN5 MoAbs, which were individually named KP2-LN5-8C2E 12-1 and KP2-LN5-8C2E 18-4. All of the MoAbs obtained in this study were classified into IgG1 subclasses. A large amount of IgG was purified from the serum-free hybridoma cell culture supernatants by protein A-Sepharose column chromatography (Amersham Pharmacia). Purified MoAbs were labeled with horseradish peroxidase (Roche Diagnostics GmbH, Mannheim, Germany) according to the periodate method (22) .

Western Blot Analysis.
Human LN5 heterotrimers or {gamma}2 chains were immunopurified from the culture supernatants of human pancreatic tumor cell line BxPC-3 using 8C2 MoAbs immobilized on a Sepharose 4B gel column. Isolated LN5 antigen was separated on a 4–20% gradient SDS-PAGE under nonreducing conditions and electrophoretically transferred onto an Immobilon polyvinylidene difluoride membrane (Millipore Co., Bedford, MA). The membrane was blocked in PBS containing 1% skim milk, and incubated in a solution containing each of the MoAbs established here. MoAbs bound on the membrane were visualized by antimouse IgG labeled with peroxidase and 4-chloro-1-naphtol substrates. The molecular masses on the membrane were determined by Kaleidoscope prestained markers (Bio-Rad Lab., Hercules, CA). Protein on the membrane was stained using coomassie brilliant blue (Wako Pure Chemical, Osaka, Japan).

Human Specimens.
Fresh blood specimens were collected from 10 healthy male volunteers (average age 35.8 ± 4.2 years; range, 28–44 years) in our laboratories. These volunteers signed the informed consent from the Department of Research and Development, Eisai Co., Ltd., approved by the Institutional Commission of Ethics. Serum was separated from each sample by centrifugation after normal blood coagulation. Each serum sample was frozen at -40° until use.

Immunoassay.
LN5, immunopurified from the culture supernatants of MKN45 cells, was basically used as the standard for the immunoassays performed in this study. We occasionally used the culture supernatants of BxPC-3 cells as the 100 units/ml control in the present experiments. The SEIA for the whole LN5 ({alpha}3ß3{gamma}2 heterotrimer) was constructed using peroxidase-labeled 2B10 MoAbs and 57 MoAbs immobilized on 96-well microplates (Nunc A/S, Roskilde, Denmark). Another SEIA format using peroxidase-labeled KP2-LN5-8C2E 12-1 and immobilized KP2-LN5-8C2E 18-4 was also performed. This two-step SEIA was performed to measure the concentration of LN5 in the cell culture supernatant, essentially according to the published method (23) . Briefly, purified IgG of 57 or KP2-LN5-8C2E 18-4 MoAb was naturally absorbed on the wells of the microplates and then blocked with PBS containing 1% skim milk. Standards and specimens were added into the wells and incubated for 1 h at room temperature. After incubation, the wells were washed three times with PBS, and the solution containing 2B10 or KP2-LN5-8C2E 12-1 coupled with peroxidases was added. One h later, the wells were washed with PBS, and tetramethyl benzidine liquid substrates were added (Sigma Chemical Co.). The enzyme reaction was terminated after 10 min of incubation by the addition of H2SO4, and the absorbance at 450 nm was measured by a T-max microplate reader (Molecular Devices Co., Sunnyvale, CA).

The levels of G2Fs in human and experimental animal biological fluids were measured by the ECL immunoassay, using KP2-LN5-8C2E 12-1 MoAb labeled with Ruthenium (Igen International, Gaithersburg, MD) and KP2-LN5-8C2E 18-4 MoAb coupled to Dynabeads M-450 magnetic beads (Dynal A. S., Oslo, Norway), on a Picolumi 8220 automated clinical laboratory analysis system (Sanko Junyaku Co., Ltd., Tokyo, Japan). Human serum specimens were thawed, and 200 µl of each sample was transferred into each ECL reaction tube. The ECL immunoassay in this study was performed automatically by the programmed instruction for the two-step immunochemical reaction (the first step including mixture of the samples and the magnetic beads; the second step including mixture of the antigen-captured magnetic beads and the labeled antibodies), as described previously (24) .

Orthotopical Transplantation Model.
MIApaca-II, HPAC, and KP-1 human pancreatic tumor cell lines were cultured according to the method described above. Eight-week-old BALB/c nu/nu mice (Charles River Japan) were anesthetized as described previously (25) . Trypsinized human pancreatic tumor cells were collected by mild centrifugation and washed three times with PBS. Seven million cells of each carcinoma line were injected into the head of the murine pancreas according to published methods (26) . Mice were separated into three groups (bearing MIApaca-II, HPAC, or KP-1) and maintained under the same conditions. Three mice randomly selected from each group were sacrificed at 2, 3, 4, and 5 weeks, after intrapancreatic tumor injection. Their primary tumors were surgically removed, and blood was collected from each heart simultaneously. The removed wet primary tumors were weighed just after dissection. Mouse sera were separated by centrifugation and kept frozen at -40° until they were used for assay. Single regression analysis of the correlation between the serum G2F levels and the pancreatic tumor weights was performed by using Excel 2000 software (Microsoft Co.).

Flow Cytometry.
Antihuman {alpha}1 integrin (clone name: 5E8D9) and antihuman {alpha}2 integrin (A2-IIE10) MoAbs were commercially available from Upstate Biotechnology (Charlottesville, VA). We purchased antihuman {alpha}5 integrin (KH/33) from Seikagaku Co. (Tokyo, Japan) and antihuman ß4 integrin (450–9D) from PharMingen/BD Bioscience (San Diego, CA). Antihuman {alpha}3 integrin (P1B5) and antihuman {alpha}v integrin (CLB-706) MoAbs were purchased from Chemicon International (Temecula, CA). AMCI 7–4 (antihuman {alpha}6 integrin MoAb), PLC37–1 (antihuman ß1 integrin), and PLC13-6 (antihuman ß3 integrin) are all murine IgG1 MoAbs, established in our laboratory. Trypsinized human pancreatic tumor cells were collected by mild centrifugation and washed three times with PBS. The cells were incubated in a solution containing antihuman integrin MoAbs at the IgG concentration of 1 µg/ml, and additionally treated with FITC-labeled antimouse IgG (Dako A/S, Glostrup, Denmark). Relative mean fluorescence intensity on the cell surfaces was measured by a FACScan system (Becton-Dickinson, San Jose, CA). Significance of differences in the integrin expression levels between the two groups was calculated by the test for equal variance using Excel 2000 software (Microsoft Co.).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Specificity of MoAbs.
Four of the murine MoAbs (19, 57, 2B10, and 8C2) we established were selected to be reactive with human LN5 derived from the gastric carcinoma cell line MKN45, which has been shown to produce an {alpha}3ß3{gamma}2 heterotrimer of LN5 (16 , 27) . The 8C2 MoAb can specifically react with LN5 derived from the human glioblastoma cell line A-172, which expresses only the {gamma}2 subunit of LN53 and the other 3 MoAbs do not react (Fig. 1)Citation . Thus, the 8C2 MoAb was defined to recognize the {gamma}2 chain of LN specifically. Both MoAbs 19 and 57 can bind to LN5 derived from the human fibrosarcoma cell line HT-1080, which expresses the ß3{gamma}2 heterodimer (27) . Therefore, the 19 and 57 MoAbs were defined as binding specifically to the LN ß3 chain. We observed that the 2B10 MoAb cannot react with the ß3 or {gamma}2 subunit of LN5, suggesting that this MoAb recognizes the {alpha}3 chain of LN. The epitope specificity of these 4 MoAbs was reconfirmed in Western blotting experiments using these LN5 derivatives. The binding epitope of the 57 MoAb is quite similar to that of the 19 MoAb, and the 57 MoAb was used in the following study.



View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Reactivity of the four established MoAbs to the heterotrimeric ({alpha}3ß3{gamma}2), the heterodimeric (ß3{gamma}2), and the {gamma}2 monomeric form of human LN5. Human LN5 heterotrimer ({alpha}3ß3{gamma}2), heterodimer (ß3{gamma}2), or {gamma}2 monomer was immunoisolated from the culture supernatants of MKN45, HT-1080, or A-172 cells, respectively. Relative binding of the MoAbs (or the antiserum as a positive control) to the LN5 antigen absorbed on the microplates was determined by measuring the absorbance obtained in the solid-phase immunoassay. PBS was used as negative control for binding. The 2B10 and 8C2 MoAbs reacted with the {alpha}3 and {gamma}2 chains, respectively. Both the 19 and 57 MoAbs recognized the ß3 chain specifically, because they could not bind to the {gamma}2 monomers.

 
In the Western blot analysis, all of the MoAbs we established bound specifically to the heterotrimeric LN5, with a molecular weight of ~440 kDa (Fig. 2)Citation . The 8C2 MoAb, as well as the KP2-LN5-8C2E 12-1 and 18-4 MoAbs, also binds to the 85 kDa and the 50 kDa fragments of the {gamma}2 chain isolated from the culture supernatants of human pancreatic carcinoma cell line BxPC-3. Considering the apparent molecular mass of these fragments, we conclude that they must be the proteolytic fragments derived from the NH2-terminal region of the LN5 {gamma}2 subunits, as reported previously (5, 6, 7) . These data revealed that the 8C2, KP2-LN5-8C2E 12-1, and KP2-LN5-8C2E 18-4 MoAbs are reactive with the same region of the {gamma}2 subunit NH2 terminus. In addition, we observed that the KP2-LN5-8C2E 18-4 MoAb is partially competitive with 8C2, but not at all with the KP2-LN5-8C2E 12-1 MoAb, for binding to LN5 immobilized on the solid phase. Therefore, we selected the combination of peroxidase-labeled KP2-LN5-8C2E 12-1 and 18-4 MoAbs immobilized on microplates for the sandwich immunoassays described.



View larger version (42K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Western blot analysis for LN {gamma}2 chain-derived fragments isolated from human pancreatic carcinoma cell culture supernatants. Detailed procedures for SDS-PAGE and immunoblotting are described in "Materials and Methods." The 8C2, KP2-LN5–8C2E 18-4, and KP2-LN5-8C2E 12-1 MoAbs were all reactive with the same fragments derived from the NH2-terminal region of the LN {gamma}2 chain, mainly consisting of fragments of ~85 kDa (A) and 50 kDa (B). All of the MoAbs recognized small amounts of intact LN5 (400 kDa) at the upper limit of the gel.

 
LN5 Levels in Human Tumor Cell Culture Supernatants.
The concentration of LN5 in culture supernatants of several human tumor cell lines was measured by the SEIA using the 57 MoAbs (anti-LN ß3) immobilized on the microplates and the 2B10 MoAbs (anti-LN {alpha}3) labeled with peroxidase, with the BxPC-3 culture supernatant as the 100 units/ml control (Fig. 3)Citation . None of the human breast carcinoma cell lines (MDA-MB-435, T-47D, MDA-MB-453, ZR-75-1, and MCF-7) secretes LN5 extracellularly. Nonepithelial tumor cell lines MG-63, U251, and SK-N-SH do not produce LN5. Both the HeLa-S3 and KB cell lines can be classified as the epidermal tumors, but they do not secrete LN5. Human prostate adenocarcinoma cell lines DU-145 and PC-3 showed moderate expression of LN5 (Fig. 3)Citation . Although LN5 was undetectable in the culture supernatant of lung carcinoma cell line A549, it was apparently observed in the supernatant of lung carcinoma cell line PC-14 and slightly detected in the supernatant of lung adenosquamous carcinoma cell line NCI-H596. Human colorectal adenocarcinoma cell lines HT-29 and SW620 secreted a slight amount of LN5. The 11 human pancreatic carcinoma cell lines were clearly classified into LN5-producing types (KP-2, KP-3, HPAC, AsPC-1, BxPC-3, and SUIT-2) or nonproducing types (KP-1, KP-4, PSN-1, PANC-1, and MIApaca-II), as shown in Fig. 3Citation .



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Relative levels of heterotrimeric LN5 ({alpha}3ß3{gamma}2) in the culture supernatants of several human tumor cell lines. All of the tumor cell lines were established from human cancers. Pancreatic carcinoma cell lines (KP-1, KP-2, KP-3, KP-4, AsPC-1, HPAC, SUIT-2, MIApaca-II, PSN-1, BxPC-3, and PANC-1), breast carcinoma cell lines (MDA-MB435, T-47D, MDA-MB-453, ZR-75-1, and MCF-7), colorectal carcinoma cell lines (HT-29 and SW620), lung carcinoma cell lines (NCI-H596, PC-14, and A549), a gastric carcinoma cell line (MKN45), prostatic carcinoma cell lines (DU145 and PC-3), an osteosarcoma cell line (MG-63), glioblastoma cell lines (U251 and SK-N-SH), a cervical carcinoma cell line (HeLa-S3), and a mouth epidermal carcinoma cell line KB were used. The relative concentrations of LN5 were measured by the SEIA using the 57 (anti-LN ß3 chain) and 2B10 (anti-LN {alpha}3 chain) MoAbs. LN5 levels in the culture supernatants were estimated by regarding those in the culture supernatants of BxPC-3 cells as 100 arbitrary units per milliliter.

 
Detection of the Monomeric LN {gamma}2 Chain by SEIA in Human Tumor Cell Culture Supernatants.
Human carcinoma cell lines including KATO-III, LX-1, WiDr, COLO205, LoVo, KP-1, and MIApaca-II were cultured. The LN {gamma}2 chain or its degraded products (mainly consisting of the 85 and 50 kDa fragments) released into the culture supernatant can be detected by the SEIA using the peroxidase-labeled KP2-LN5-8C2E 12-1 and 18-4 MoAbs immobilized on the microplates, and MKN45-derived LN5 as the assay standards (Fig. 4)Citation . As expected, intact LN5 heterotrimers were also detectable with the SEIA system using the KP2-LN5-8C2E 12-1 and 18-4 MoAbs, because most of the tumor cell lines presented in Fig. 4Citation secrete the LN5 heterotrimeric form ({alpha}3ß3{gamma}2), which is detected efficiently by this SEIA (Fig. 4)Citation . KATO-III cells were shown to produce the LN5 heterotrimeric form, but the secreted levels of the {gamma}2 chain were relatively elevated. The human lung carcinoma cell line LX-1 expresses all of the subunits, as well as the 3 colorectal adenocarcinoma cell lines WiDr, COLO205, and LoVo. It is surprising that the pancreatic carcinoma cell line KP-1 secretes only the monomeric {gamma}2 chain and expresses neither the {alpha}3 nor ß3 chains (Fig. 4)Citation . In contrast, another pancreatic carcinoma cell line, HPAC, efficiently expresses high amounts of the LN {gamma}2 chain into the culture supernatants at a concentration of >=10,000 ng/ml (not shown in Fig. 4Citation ). These data also showed that there was no expression of the {alpha}3, ß3, or {gamma}2 subunits of LN5 by cells of the human pancreatic carcinoma cell line MIApaca-II.



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Measurement of the monomeric {gamma}2 chain in the culture supernatants of human carcinoma cell lines. The concentrations of the LN5 heterotrimer ({alpha}3ß3{gamma}2) were measured by the SEIA using the 57 (anti-LN ß3 chain) and 2B10 (anti-LN {alpha}3 chain) MoAbs. The levels of the {gamma}2 chain monomer were determined by the SEIA using KP2-LN5-8C2E 18-4 and KP2-LN5-8C2E 12-1 MoAbs (anti-LN {gamma}2 chain). Purified LN5 was used as the assay standards for both SEIAs. The pancreatic carcinoma cell line KP-1 solely expresses the monomeric form of the {gamma}2 chain.

 
Integrins Expressed on Cells of the Pancreatic Carcinoma Cell Lines.
The relative levels of {alpha}1, {alpha}2, {alpha}3, {alpha}5, {alpha}6, {alpha}v, ß1, ß3, and ß4 integrins expressed on cells of the pancreatic tumor cell lines were quantified by flow cytometric analysis. We additionally averaged the relative expression levels of these integrins on cells of the 6 cell lines secreting LN5 or the 5 nonsecreting cell lines, separately (Table 1)Citation . The average levels of {alpha}2 or ß1 integrin are quite similar (relative ratio of 0.99 or 1.09, respectively) between these two groups, but the levels of ß4 integrin on cells of LN5-producing cell lines are drastically elevated compared with those on cells of nonproducing cell lines (relative ratio of 8.19). The expression levels of {alpha}1 or {alpha}3 integrins seemed to increase moderately in the 6 cell lines secreting LN5 (1.4 or 1.44, respectively) as compared with those in the cells of the nonsecreting cell lines, but no statistical significance was observed. Up-regulation of {alpha}6 integrins (ratio, 2.22) and down-regulation of {alpha}vß3 integrins (ratios of 0.86 and 0.53, respectively) on cells of the LN5-producing cell lines was observed, but differences in these changes were not significant. On the contrary, the cell lines without LN5 secretion tended to express significantly higher levels of cell surface {alpha}5 integrin than cells of the LN5-producing cell lines (Table 1)Citation . Statistically significant differences were observed between LN5-secreting cells and LN-5 nonsecreting cells in the expression levels of ß4 integrins (P < 0.002) and {alpha}5 integrins (P < 0.002).


View this table:
[in this window]
[in a new window]

  		Table 1 Average levels of integrin subunit expression on cells of LN5-secreting or nonsecreting human pancreatic carcinoma cell lines

 
Measurement of LN5 Levels in Human Sera.
We could immunologically detect LN5 in human sera from 10 healthy male subjects using the ECL sandwich immunoassay with two different MoAbs reacting to the distant sites of the NH2-terminal domain of the {gamma}2 chain (KP2-LN5–8C2E 12-1 and 18-4). On the contrary, any of the SEIAs described here were not suitable for the detection of the circulating form of LN5 or its fragments, suggesting that high assay sensitivity is necessary for the quantification of the low amount of LN5 antigen in the human circulation. In the construction of the ECL assay, none of the other MoAbs besides KP2-LN5-8C2E 12-1 and 18-4 was applicable for immunodetection of LN5 in the human circulation. These results revealed that the ECL two-site immunoassay using KP2-LN5-8C2E 12-1 as a detector and KP2-LN5-8C2E 18-4 as a capture antibody is the only method that enables measurement of the concentration of the LN5 antigen in the human circulation. The mean concentration of LN5 in the 10 human individuals in this study was 39.2 ± 10.3 ng/ml (mean ± SD).

Levels of Circulating LN5 in Nude Mice Transplanted with Human Carcinoma Cells.
All 3 of the human pancreatic tumor cell lines were able to grow in the pancreas of nude mice. There was no detectable LN5 antigen in the circulation of mice transplanted with MIApaca-II cells, because they have no ability to express LN5 in vitro (Fig. 5B)Citation . Culture supernatants of HPAC cells contain high levels of LN5 (Fig. 3)Citation , and these cells also secrete a large amount of LN5 into the circulation of mice (Fig. 5A)Citation . LN5 or its {gamma}2-derived fragments drastically increased, along with the growth of the primary tumor, in the circulation of nude mice bearing HPAC cells at the primary site of the pancreas (mean ± SD: 351 ± 33 ng/ml, 5 weeks after transplantation). Cells of the human pancreatic carcinoma cell line KP-1 were shown to secrete a small amount of LN {gamma}2 subunit monomer solely (Fig. 4)Citation . Additionally, an increase in the monomeric {gamma}2 chain or its degraded fragments was also investigated (87.9 ± 82 ng/ml, 5 weeks after transplantation) in the sera of nude mice transplanted with KP-1 pancreatic tumor cell lines (Fig. 5C)Citation . Statistically significant correlation was observed between the serum concentrations and the weights of the primary tumors in the mice bearing HPAC cells, as the correlation coefficient was 0.77 (P < 0.01). The similar correlation was found significantly in the KP-1-transplanted nude mice, as the correlation coefficient was 0.71 (P < 0.02). These results reasonably explain that the elevated levels of circulating LN5 detected by this ECL assay are the result of increases in heterotrimers {alpha}3ß3{gamma}2 or monomeric {gamma}2 production in the primary sites of growing carcinomas.



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Primary tumor growth and circulating levels of LN {gamma}2 in nude mice orthotopically transplanted with human pancreatic carcinoma cell lines. Human pancreatic carcinoma cell lines including HPAC (A), MIApaca-II (B), and KP-1 (C) were orthotopically transplanted into nude mice. Blood collection, tumor dissection, and the ECL assay for LN {gamma}2 levels in serum samples were performed at 2, 3, 4, and 5 weeks after implantation, as described in "Materials and Methods." Each square mark designates the average levels of data obtained from three animals; bars, ± SD. The circulating levels were significantly correlated with the weights of the primary tumors in the mice transplanted with HPAC (r = 0.77; P < 0.01) and in those transplanted with KP-1 (r = 0.71; P < 0.02). OT, orthotopic transplantation.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Some basement membrane constituents are well known to be degraded into small domains or peptide fragments by several proteases from invasive carcinoma cells (28, 29, 30) . Soluble degradation products of LNs in human biological fluids have been studied extensively and applied to clinical diagnostics for certain cancers (31 , 32) . We have already investigated that the NH2-terminal fragments of the LN {gamma}1 chain, initially designated as the B2 chain, are present in the human circulation and excreted frequently into the urine of lung cancer patients (23) . The present study showed that G2Fs are also proteolytically processed in vivo and released into the human circulation.

LN {gamma}1 chain is proposed to be assembled typically with each ß1 or ß2 chain in the first step, and secondly with either the {alpha}1, {alpha}2, {alpha}4, or {alpha}5 chain, resulting in the intracellular formation of at least 8 types of LN heterotrimers (2) . On the other hand, the {gamma}2 chain is complexed with the ß3 chain into the heterodimer, which is also associated with the {alpha}3 chain, finally resulting in the LN5 heterotrimer (33) . Considering these distinct chain-assembly processes for LN isoforms, it is presumed that the NH2-terminal fragments of the {gamma}1 chain in the human circulation are derived from the total of these different LN isoforms expressed in several tissues throughout the body (1 , 2) . Therefore, circulating G2Fs form a remarkable contrast with those of the {gamma}1 chain in the following characteristics. First, we can positively indicate that the {gamma}2 chain fragments must be generated solely from LN5 molecules expressed specifically in epithelial tissues. Second, the released levels of G2Fs into the circulation may reflect new production of the LN {gamma}2 chain by the epithelial cells, rather than proteolytic degradation of the endogenous ECM containing LN {gamma}2 chains. We are reasonably certain that the increase in the circulating levels of G2Fs reflects newly deposited LN5 into the ECM in vivo.

We revealed that cells of the human pancreatic tumor cell line BxPC-3 actually secrete G2Fs with apparent molecular weights of 50 kDa and 85 kDa (Fig. 2)Citation . We also found that the molecular weights of the G2Fs secreted from cells of the KP-2 or HPAC cell lines were quite similar to those from BxPC-3 cells (data not shown), suggesting that these human carcinoma cells generate the identical processing proteases that cleave the NH2-terminal region of LN {gamma}2. The previous report demonstrated that most of the NH2-terminal processing of the {gamma}2 chain is mediated by cellular MT1-MMP rather than by the other MMPs (34) . Therefore, we hypothesized that G2Fs with molecular weights of 50 and 85 kDa can be simultaneously generated in these pancreatic tumor cell lines only by MT1-MMP-mediated processing (7) .

We observed that the LN5 heterotrimer could be secreted from cells of some human tumor cell lines used in this study (Fig. 3)Citation . No apparent production of LN5 was detected in any of the breast carcinoma cell lines (Fig. 3)Citation . This result corresponds well with previous data suggesting the diminished expression of LN5 mRNA in the breast tumor cell lines or tissues (35) . Cells of prostatic or lung carcinoma cell lines secreted high or moderate amounts of LN5 extracellularly in vitro (Figs. 3Citation and 4)Citation , offering the excellent prospect for their high potential to express LN5 in vivo. It is very interesting that active secretion of LN5 was observed only in 6 of 11 lines of human pancreatic carcinoma cells used here, indicating that carcinomas in human pancreatic cancer patients can be clinicopathologically classified into distinct groups of LN5-producing types or nonproducing types. Such a pathological classification has been performed already for some human cancers (12, 13, 14, 15) , and circulating markers for monitoring LN5 production in vivo have been needed for a long time. Our present data showed that immunodetectable LN5 in the circulation of nude mice originates from the implanted human tumor cell lines and that increases in the level possibly indicate enhanced production of LN {gamma}2 by the pancreatic tumors. The elevation of LN {gamma}2 concentrations in mouse sera was significantly correlated with the growth of the primary tumor from HPAC- or KP-1-transplanted cells (Fig. 5, A and C)Citation .

This report also revealed for the first time that cellular expression of ß4 integrin on cells of the established human tumor cell lines is significantly correlated with their ability to produce LN5 heterotrimers. It is well known that ß4 integrins are complexed only with {alpha}6 subunits to form the heterodimeric integrin receptors specific to LN5, concentrated in the hemidesmosome structures of epithelium (2 , 4 , 19) . Intracellular signaling by the {alpha}6ß4 integrin is known to stimulate carcinoma cell invasion, and this detailed function involves the remodeling of the LN5-rich basement membranes and hemidesmosome turnover, leading to the acquisition of a motile, invasive phenotype (19 , 36) . In the present study, we explored the possibility that cells of the human pancreatic ductal carcinoma cell line HPAC express the cell surface {alpha}6ß4 integrins (data not shown), and actively secrete LN5 in vitro and in vivo (Fig. 3Citation ; Fig. 5ACitation ). Cells of the human pancreatic ductal carcinoma cell line AsPC-1 are known to be highly invasive in nude mice when they are orthotopically transplanted (37) , and here we showed that they can express high amount of LN5 (Fig. 3)Citation . We preliminarily found that the circulating levels of G2Fs drastically increased in all of the mice orthotopically transplanted with AsPC-1 cells (data not shown). HPAC cells, as well as AsPC-1 cells, showed extensive peritoneal dissemination in the transplanted mice (data not shown). The primary tumor weights did not drastically increase in the nude mice transplanted with HPAC cell lines 4 and 5 weeks after transplantation, as compared with those in the mice transplanted with MIApaca-II or KP-1 (Fig. 5, A–C)Citation , because growing HPAC cells frequently form the cell spheroidal islands and migrate into the peritoneum from the primary sites. Therefore, the serum G2F concentration in the HPAC-transplanted mice appeared to be elevated simultaneously with primary tumor peritoneal dissemination. These data revealed that an increase in the level of circulating G2Fs indicates the progression of the invasive pancreatic carcinoma in the host (Fig. 6)Citation .



View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Schematic representation of tumor cell secretion and proteolytic cleavage of G2Fs, and the detection process by the sandwich ECL immunochemical techniques. Invasive carcinomas actively secrete LN5 heterotrimers and shed the NH2-terminal region of the {gamma}2 chain. Some of these tumors can express the monomeric {gamma}2 chains, which may be processed proteolytically. As a result, 50 and 85 kDa fragments may be released into circulation, and detected by the sensitive ECL immunoassay constructed in the present study.

 
We mentioned that the monomeric LN {gamma}2 chain is apparently secreted from cells of the KP-1 pancreatic carcinoma cell line (Fig. 4)Citation . This cell line is novel in that it secretes only the monomer of the {gamma}2 chain, without expression of the {alpha}3 or ß3 subunits. In the data presented in Fig. 4Citation , relatively elevated levels of the {gamma}2 chain were observed in the culture supernatants of the tumor cell lines secreting LN5, as compared with the levels of the heterotrimer. In particular, the elevation of the {gamma}2 chain concentration is most significant in the culture of KATO-III (Fig. 4)Citation . Possible interpretation on this phenomenon is that the LN {gamma}2 monomeric form or its degraded fragments are constitutively expressed by almost all of these carcinoma cells, except for the heterotrimeric form of LN5 (schematically represented in Fig. 6Citation ). Some stomach carcinoma cells have been shown to express the monomeric {gamma}2 and the heterotrimer ({alpha}3ß3{gamma}2) simultaneously (16) . Clinical significance of circulating G2F as an invasion marker is also supported by the previous data demonstrating the expression of the monomeric form of the LN {gamma}2 chain in human malignant tissues, not associated with {alpha}3 or ß3 chains, is so prominent as to be recognized as an important histochemical marker for epithelial carcinoma invasiveness (16 , 17 , 38) . Additionally, we could hardly immunodetect the heterotrimer ({alpha}3ß3{gamma}2) or the heterodimer (ß3{gamma}2) form in human sera (data not shown), suggesting that circulating G2F level is solely effective in estimating the invasive ability of epithelial tumors by using sera from the patients.

Expression levels of the LN {gamma}2 monomer in KP-1 pancreatic carcinoma cells were found to be relatively lower in vitro and in vivo (Fig. 4Citation ; Fig. 5CCitation ), as compared with those in HPAC cell lines (Fig. 5A)Citation . The in vitro expression potency for soluble LN5 or {gamma}2 chains of HPAC cell lines was shown to be ~25 times higher than that of KP-1 cell lines (comments in Results and Fig. 4Citation ). Four weeks after orthotopic transplantation, the average circulating level for LN {gamma}2 in mice bearing HPAC cells was quantified (mean ± SD; 355.3 ± 105.7 ng/ml) and defined to be ~20 times higher than that (17.7 ± 13.3 ng/ml) in the KP-1-transplanted mice (Fig. 5, A and C)Citation . Because the dissected tumor weights of HPAC and KP-1 were found to be quite similar (0.23 ± 0.049 g and 0.258 ± 0.148 g, respectively) at that time, we are confident that cells of the HPAC cell line have an enhanced productivity for LN5 also in the primary site of the nude mice, as well as in the in vitro cultured condition. These results positively suggested that serum concentrations of LN {gamma}2 can accurately reflect in vivo expression of LN5 or monomeric {gamma}2 chains in the primary carcinomas.

Although detailed cellular functions and the frequency of the monomeric {gamma}2 chain expression in human epithelial carcinomas are still unclear, it should be mentioned that the present ECL assay is of great physiological value, with the ability to detect the cellular expression of the LN {gamma}2 monomer in vivo (Fig. 6)Citation . The NH2-terminal region of LN {gamma}2 chain can bind to type VII collagen, heparin, sulfatide, nidogen-1, fibulin-1C, or -2 (39, 40, 41) , and these {gamma}2-associated molecules may function in any processes of epithelial migration. Some additional pathophysiologic and cell biology studies are required to understand the relationship between LN {gamma}2 production and tumor invasiveness.

In conclusion, we suggest that the circulating G2F level has the potential to be a surrogate marker (instead of clinicopathologic analysis quantifying tumor cell malignancy) when it is used in diagnostics for human cancers. In the mRNA analysis published previously, the normal pancreas is reported to be one of the human organs expressing little LN5 molecule (27) . On the contrary, human pancreatic carcinomas secrete large amounts of LN5, and prefer to adhere and migrate on the newly deposited LN5 in their ECM (42) . This phenomenon apparently agrees with the previous immunohistochemical data describing the prominent LN {gamma}2 deposition in human pancreatic carcinomas (43) . The clinical diagnostic performance of this analysis will be described in our future reports.


   ACKNOWLEDGMENTS
 
We thank Yuji Yamamoto, Kenichi Nomoto, and Kentaro Yoshimatsu (Drug Discovery Laboratory II, Eisai Co., Ltd.) for suggestions and technical support with the orthotopic transplantation experiments. Purified LN materials and the valuable information about LN from A-172 cell lines were provided from Yuji Fukushima (Research Institute, Osaka Medical Center for Maternal and Child Health, Osaka, Japan4 ). Valuable discussions were also held with Nariaki Matsuura (School of Medicine and Allied Health Science, Osaka University, Osaka, Japan).


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Diagnostic Department, Eisai Co., Ltd., Tokodai 5-1-3, Tsukuba, Ibaraki 300-2635, Japan. Phone: 81-298-47-5682; Fax: 81-298-47-4547; E-mail: m1-katayama{at}eisai.co.jp Back

2 The abbreviations used are: LN, laminin; ECM, extracellular matrix; MMP, matrix metalloprotease; MT1-MMP, membrane-type 1 matrix metalloprotease; G2F, laminin {gamma}2 NH2-terminal fragment; MoAb, monoclonal antibody; SEIA, sandwich enzyme immunoassay; ECL, electrochemiluminescence. Back

3 Y. Fukushima, personal communication. Back

4 Present address: Department of Neurosurgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-0025, Japan. Back

Received 6/17/02. Accepted 10/29/02.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Timple R., Brown J. C. The laminins. Matrix Biol., 14: 275-281, 1994.[Medline]
  2. Colognato H., Yurchenco P. D. Form and function: the laminin family of heterotrimers. Dev. Dyn., 218: 213-234, 2000.[Medline]
  3. Rousselle P., Lunstrum G. P., Keene D. R., Burgeson R. E. Kalinin: an epithelium-specific basement membrane adhesion molecule that is a component of anchoring filaments. J. Cell Biol., 114: 567-576, 1991.[Abstract/Free Full Text]
  4. Carter W. G., Ryan M. C., Gahr P. J. Epiligrin, a new cell adhesion ligand for integrin {alpha}3ß1 in epithelial basement membranes. Cell, 65: 599-610, 1991.[Medline]
  5. Marinkovich M. P., Lunstrum G. P., Burgeson R. E. The anchoring filament protein kalinin is synthesized and secreted as a high molecular weight precursor. J. Biol. Chem., 267: 17900-17906, 1992.[Abstract/Free Full Text]
  6. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W. G., Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science (Wash. DC), 277: 225-228, 1997.[Abstract/Free Full Text]
  7. Koshikawa N., Giannelli G., Cirulli V., Miyazaki K., Quaranta V. Role of cell surface metalloprotease MT-1-MMP in epithelial cell migration over laminin-5. J. Cell Biol., 148: 615-624, 2000.[Abstract/Free Full Text]
  8. Amano S., Scott I. C., Takahara K., Koch M., Champliaud M-F., Gerecke D. R., Keene D. R., Hudson D. L., Nishiyama T., Lee S., Greenspan D. S., Burgeson R. E. Bone morphogenetic protein 1 is an extracellular processing enzyme of the laminin 5 {gamma}2 chain. J. Biol. Chem., 275: 22728-22735, 2000.[Abstract/Free Full Text]
  9. Lohi J. Laminin-5 in the progression of carcinomas. Int. J. Cancer, 94: 763-767, 2001.[Medline]
  10. Miyazaki K., Kikkawa Y., Nakamura A., Yasumitsu H., Umeda M. A large cell-adhesive scatter factor secreted by human gastric carcinoma cells. Proc. Natl. Acad. Sci. USA, 90: 11767-11771, 1993.[Abstract/Free Full Text]
  11. Fukushima Y., Ohnishi T., Arita N., Hayakawa T., Sekiguchi K. Integrin {alpha}3ß1-mediated interaction with laminin-5 stimulates adhesion, migration, and invasion of malignant glioma cells. Int. J. Cancer, 76: 63-72, 1998.[Medline]
  12. Pyke C., Rømer J., Kallunki P., Lund L. R., Ralfkiær E., Danø K., Tryggvason K. The {gamma}2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am. J. Path., 145: 782-791, 1994.[Abstract]
  13. Pyke C., Salo S., Ralfkiær E., Rømer J., Danø K., Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res., 55: 4132-4139, 1995.[Abstract/Free Full Text]
  14. Ono Y., Nakanishi Y., Ino Y., Niki T., Yamada T., Yoshimura K., Saikawa M., Nakajima T., Hirohashi S. Clinicopathologic significance of laminin-5 {gamma}2 chain expression in squamous cell carcinoma of the tongue. Cancer (Phila.), 85: 2315-2321, 1999.[Medline]
  15. Skyldberg B., Salo S., Eriksson E., Aspenblad U., Moberger B., Tryggvason K., Auer G. Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl. Cancer Inst., 91: 1882-1887, 1999.[Abstract/Free Full Text]
  16. Koshikawa N., Moriyama K., Takamura H., Mizushima H., Nagashima Y., Yanoma S., Miyazaki K. Overexpression of laminin {gamma}2 chain monomer in invading gastric carcinoma cells. Cancer Res., 59: 5596-5601, 1999.[Abstract/Free Full Text]
  17. Hlubek F., Jung A., Kotzor N., Kirchner T., Brabletz T. Expression of the invasion factor laminin {gamma}2 in colorectal carcinomas is regulated by ß-catenin. Cancer Res., 61: 8089-8093, 2001.[Abstract/Free Full Text]
  18. Amano S., Nishiyama T., Burgeson R. E. A specific and sensitive ELISA for laminin-5. J. Immunol. Methods, 224: 161-169, 1999.[Medline]
  19. Mercurio A. M., Rabinovitz I., Shaw L. M. The {alpha}6ß4 integrin and epithelial cell migration. Curr. Opin. Cell Biol., 13: 541-545, 2001.[Medline]
  20. Giannelli G., Antonaci S. Biological and clinical relevance of laminin-5 in cancer. Clin. Exp. Metast., 18: 439-443, 2001.
  21. Jimi S., Shono T., Tanaka M., Kono A., Yamada Y., Shudo K., Kuwano M. Effect of retinoic acid on morphological changes of human pancreatic cancer cells on collagen gels: a possible association with the metastatic potentials. Oncol. Res., 10: 7-14, 1998.[Medline]
  22. Harlow E., Lane D. . Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press New York 1988.
  23. Katayama M., Kamihagi K., Hirai S., Kurome T., Murakami K., Hino F., Kato I. Urinary laminin fragments as a tumour marker potentially reflecting basement membrane destruction. Br. J. Cancer, 65: 509-514, 1992.[Medline]
  24. Namba Y., Usami M., Suzuki O. Highly sensitive electrochemiluminescence immunoassay using the Ruthenium chelate-labeled antibody bound on the magnetic micro beads. Ana. Sci., 15: 1087-1093, 1999.
  25. Funahashi Y., Koyanagi N., Sonoda J., Kitoh K., Yoshimatsu K. Rapid development of hepatic metastasis with high incidence following orthotopic transplantation of murine colon 38 carcinoma as intact tissue in syngeneic C57BL/6 mice. J. Surg. Oncol., 71: 83-90, 1999.[Medline]
  26. Zervos E. E., Norman J. G., Gower W. R., Franz M. G., Rosemurgy A. S. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J. Surg. Res., 69: 367-371, 1997.[Medline]
  27. Mizushima H., Miyagi Y., Kikkawa Y., Yamanaka N., Yasumitsu H., Misugi K., Miyazaki K. Differential expression of laminin-5/ladsin subunits in human tissues and cancer cell lines and their induction by tumor promoter and growth factors. J. Biochem., 120: 1196-1202, 1996.[Abstract/Free Full Text]
  28. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol., 10: 415-433, 2000.[Medline]
  29. Miyamoto K. K., McSherry S. A., Robins S. P., Besterman J. M., Hohler J. L. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J. Urol., 151: 909-913, 1994.[Medline]
  30. Feldman A. L., Tamarkin L., Paciotti G. F., Simpson B. W., Linehan W. M., Yang J. C., Fogler W. E., Turner E. M., Alexander H. R., Jr., Libutti S. K. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin. Cancer Res., 6: 4628-4634, 2000.[Abstract/Free Full Text]
  31. Brocks D. G., Strecker H., Neubauer H. P., Timple R. Radioimmunoassay of laminin in serum and its application to cancer patients. Clin. Chem., 32: 787-791, 1986.[Abstract/Free Full Text]
  32. Byers L. J., Osborne J. L., Carson L. F., Carter J. R., Haney A. F., Weinberg J. B., Ramakrishnan S. Increased levels of laminin in ascitic fluid of patients with ovarian cancer. Cancer Lett., 88: 67-72, 1995.[Medline]
  33. Matsui C., Wang C. K., Nelson C. F., Bauer E. A., Hoeffler W. K. The assembly of laminin-5 subunits. J. Biol. Chem., 270: 23496-23503, 1995.[Abstract/Free Full Text]
  34. Gilles C., Polette M., Coraux C., Tournier J-M., Meneguzzi G., Munaut C., Volders L., Rousselle P., Birembaut P., Foidart J-M. Contribution of MT1-MMP and of human laminin-5 {gamma}2 chain degradation to mammary epithelial cell migration. J. Cell Sci., 114: 2967-2976, 2001.[Abstract/Free Full Text]
  35. Martin K. J., Kwan C-P., Nagasaki K., Zhang X., O’Hare M. J., Kaelin C. M., Burgeson R. E., Pardee A. B., Sager R. Down-regulation of laminin-5 in breast carcinoma cells. Mol. Med., 4: 602-613, 1998.[Medline]
  36. Rabinovitz I., Gipson I. K., Mercurio A. M. Traction forces mediated by {alpha}6ß4 integrin: implications for basement membrane organization and tumor invasion. Mol. Biol. Cell, 12: 4030-4043, 2001.[Abstract/Free Full Text]
  37. Haberern-Blood C., Liotta L. A., Rao C. N., Kupchik H. Z. Laminin expression by human pancreatic carcinoma cells in the nude mouse and in culture. J. Natl. Cancer Inst., 79: 891-897, 1987.
  38. Sordat I., Rousselle P., Chaubert P., Petermann O., Aberdam D., Bosman F. T., Sordat B. Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int. J. Cancer, 88: 708-717, 2000.[Medline]
  39. Utani A., Nomizu M., Yamada Y. Fibulin-2 binds to the short arms of laminin-5 and laminin-1 via conserved amino acid sequences. J. Biol. Chem., 272: 2814-2820, 1997.[Abstract/Free Full Text]
  40. Rousselle P., Keene D. R., Ruggiero F., Champliaud M-F., van der Rest M., Burgeson R. E. Laminin-5 binds the NC-1 domain of type VII collagen. J. Cell Biol., 138: 719-728, 1997.[Abstract/Free Full Text]
  41. Sasaki T., Göhring W., Mann K., Brakebusch C., Yamada Y., Fässler R., Timple R. Short arm region of laminin-5 {gamma}2 chain: structure, mechanism of processing and binding to heparin and proteins. J. Mol. Biol., 314: 751-763, 2001.[Medline]
  42. Tani T., Lumme A., Linnala A., Kivilaakso E., Kiviluoto T., Burgeson R. E., Kangas L., Leivo I., Virtanen I. Pancreatic carcinomas deposit laminin-5, preferably adhere to laminin-5, and migrate on the newly deposited basement membrane. Am. J. Pathol., 151: 1289-1302, 1997.[Abstract]
  43. Soini Y., Määtä M., Salo S., Tryggvason K., Autio-Harmainen H. Expression of the laminin {gamma}2 chain in pancreatic adenocarcinoma. J. Pathol., 180: 290-294, 1996.[Medline]



This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
P. M. Carpenter, A. V. Dao, Z. S. Arain, M. K. Chang, H. P. Nguyen, S. Arain, J. Wang-Rodriguez, S.-Y. Kwon, and S. P. Wilczynski
Motility Induction in Breast Carcinoma by Mammary Epithelial Laminin 332 (Laminin 5)
Mol. Cancer Res., April 1, 2009; 7(4): 462 - 475.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. C. Lee, Y. K. Kang, W. H. Kim, Y. J. Jang, D. J. Kim, I. Y. Park, B. H. Sohn, H. A. Sohn, H. G. Lee, J. S. Lim, et al.
Functional and Clinical Evidence for NDRG2 as a Candidate Suppressor of Liver Cancer Metastasis
Cancer Res., June 1, 2008; 68(11): 4210 - 4220.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P. A.B. Klemmt, J. G. Carver, P. Koninckx, E. J. McVeigh, and H. J. Mardon
Endometrial cells from women with endometriosis have increased adhesion and proliferative capacity in response to extracellular matrix components: towards a mechanistic model for endometriosis progression
Hum. Reprod., December 1, 2007; 22(12): 3139 - 3147.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Ido, A. Nakamura, R. Kobayashi, S. Ito, S. Li, S. Futaki, and K. Sekiguchi
The Requirement of the Glutamic Acid Residue at the Third Position from the Carboxyl Termini of the Laminin {gamma} Chains in Integrin Binding by Laminins
J. Biol. Chem., April 13, 2007; 282(15): 11144 - 11154.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
M. Takkunen, R. Grenman, M. Hukkanen, M. Korhonen, A. Garcia de Herreros, and I. Virtanen
Snail-dependent and -independent Epithelial-Mesenchymal Transition in Oral Squamous Carcinoma Cells
J. Histochem. Cytochem., November 1, 2006; 54(11): 1263 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
T. Xiao, W. Ying, L. Li, Z. Hu, Y. Ma, L. Jiao, J. Ma, Y. Cai, D. Lin, S. Guo, et al.
An Approach to Studying Lung Cancer-related Proteins in Human Blood
Mol. Cell. Proteomics, October 1, 2005; 4(10): 1480 - 1486.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. E. Banks, A. J. Stanley, D. A. Cairns, J. H. Barrett, P. Clarke, D. Thompson, and P. J. Selby
Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry
Clin. Chem., September 1, 2005; 51(9): 1637 - 1649.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Qian, J. Niu, M. Li, P. J. Chiao, and M.-S. Tsao
In vitro Modeling of Human Pancreatic Duct Epithelial Cell Transformation Defines Gene Expression Changes Induced by K-ras Oncogenic Activation in Pancreatic Carcinogenesis
Cancer Res., June 15, 2005; 65(12): 5045 - 5053.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Gesierich, C. Paret, D. Hildebrand, J. Weitz, K. Zgraggen, F. H. Schmitz-Winnenthal, V. Horejsi, O. Yoshie, D. Herlyn, L. K. Ashman, et al.
Colocalization of the Tetraspanins, CO-029 and CD151, with Integrins in Human Pancreatic Adenocarcinoma: Impact on Cell Motility
Clin. Cancer Res., April 15, 2005; 11(8): 2840 - 2852.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katayama, M.
Right arrow Articles by Sekiguchi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katayama, M.
Right arrow Articles by Sekiguchi, K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online